Why Saudi Arabia Is Becoming a Global Hub for Health Innovation
There’s been a lot written about Saudi Arabia over the past few years. Big projects. Big numbers. Big ambition.
Some of it is overhyped. Some of it is misunderstood.
But if you look specifically at healthcare—and more broadly at health innovation—something quite real is happening. And the numbers back it up.
Saudi Arabia is positioning itself not just as a market for healthcare solutions, but as a place where those solutions are built, tested, and scaled. Understanding the difference matters enormously for any company thinking about the region.
The scale of commitment is real
Start with the investment picture, because it sets the context for everything else.
The Saudi government allocated approximately USD 69 billion to health and social development in its 2025 budget—one of the largest public expenditure lines across any government sector. Total healthcare spending in the Kingdom exceeded SAR 190 billion in 2025, representing roughly 6–7% of GDP.
The overall healthcare market is valued at around USD 139 billion in 2025, with projections putting it at USD 259 billion by 2032—a compound annual growth rate of approximately 9.4%.
That’s not a niche opportunity. That’s structural scale.
Under Vision 2030, the government has committed to investing over USD 65 billion in healthcare infrastructure—reorganising services across 21 regional health clusters, expanding primary care, and significantly increasing private sector participation. The target is to raise the private sector’s share of healthcare delivery from 40% to 65% by 2030, which includes the privatisation of 290 hospitals and 2,300 primary health centres.
Progress is already visible. Healthcare coverage across the Kingdom rose from 86% to 96.4% between 2019 and 2023. The SEHA Virtual Hospital, launched in 2022, is now the largest of its kind globally, connecting over 150 hospitals with more than 30 specialised health services.
This isn’t just about infrastructure
It’s easy to read those figures and conclude that Saudi is simply building hospitals. That would be a significant misreading of what’s actually happening.
The more interesting shift is in where investment is being directed.
The Health Sector Transformation Programme is explicitly focused on structural change: digital infrastructure, preventative care, personalised medicine, AI-enabled services, and local capability building. These aren’t incremental upgrades to an existing system. They represent a deliberate effort to rebuild the system around a different set of principles.
For companies in digital health, medtech, diagnostics, or life sciences, this is the relevant context. Saudi isn’t looking to purchase solutions and fit them around an existing structure. It’s building new infrastructure from the ground up—and looking for partners who can contribute to that process.
Digital health is a core pillar, not an add-on
Saudi Arabia’s digital health market was valued at approximately USD 2.4 billion in 2024, with analysts projecting sustained growth of 20–24% annually over the coming decade—reaching an estimated USD 11–17 billion by the early 2030s.
The national infrastructure underpinning this growth is already taking shape.
The National Health Information Center (NHIC) is building the kingdom’s electronic health record framework and driving interoperability across the system. The Wasfaty platform has transformed digital prescribing at scale. NUPCO—the national unified procurement company—launched a digital healthcare marketplace in Q1 2025, extending its procurement capabilities beyond government hospitals to private clinics and SMEs.
At LEAP 2025, over USD 14.9 billion in investments in AI and digital technologies were announced across sectors, with healthcare among the primary beneficiaries.
For companies operating in health data, AI diagnostics, remote monitoring, or digital infrastructure, what’s being built in Saudi is not a pilot programme. It’s national-scale infrastructure, and the procurement pathways are becoming more structured and accessible as a result.
Biotech and life sciences are rising fast
Alongside digital health, there’s a quieter but equally significant shift happening in biotech and life sciences.
Saudi Arabia’s National Biotechnology Strategy—anchored to Vision 2030—has four core pillars: vaccines and biomanufacturing localisation, genomics, and plant biotech. The intent is clear: to move from being a consumer of innovation to a contributor to it.
King Abdulaziz City for Science and Technology (KAEC) life sciences centre is very active. In addition, in 2025, multiple funds were announced with explicit biotech mandates, including IB Ventures and Sarat Ventures’ Y Innovations Biotech Fund, each with USD 50 million commitments. A Saudi Biotech Accelerator, developed in partnership with global incubator BioLabs, launched the same year.
On the genomics side, NUPCO awarded a three-year contract in 2025 covering more than 930,000 genetic testing services across 83 public hospitals, a signal of both scale and intent.
For companies in precision medicine, genomics, biomanufacturing, or rare diseases, this is a market that is actively building capacity and looking for credible partners to accelerate that process.
A system open to change
One of the less-discussed aspects of the Saudi market is its genuine openness to new approaches—not just in rhetoric, but in practice.
In more mature healthcare systems, innovation is often slowed by legacy infrastructure, entrenched procurement processes, and competing institutional interests. These are real constraints.
Saudi has some of those challenges, but it also has something different: a system that is still being actively shaped. That creates space for new models of care, new technologies, and new ways of working that would face far more friction elsewhere.
The health clusters—of which more than 80 are being established across the Kingdom—are designed to operate with a degree of autonomy that allows for faster decision-making than traditional Ministry of Health procurement. That matters for companies looking to pilot, iterate, and scale.
The workforce picture
No healthcare system functions without people, and Saudi is investing heavily here too.
The kingdom aims to recruit 175,000 healthcare professionals by 2030, including 69,000 doctors, 64,000 nurses, and 42,000 allied health workers. More than 200,000 new jobs are expected to be created in the sector over the course of Vision 2030.
This workforce expansion creates parallel opportunities in healthcare education, training technology, simulation, and allied health, areas that often receive less attention than headline medtech or digital health, but where real demand exists.
Geography matters more than most companies realise
Saudi Arabia doesn’t exist in isolation. Its geographic and diplomatic position gives it a reach that extends well beyond its own borders.
The GCC healthcare market—Saudi Arabia, UAE, Qatar, Kuwait, Bahrain, and Oman—is projected to reach USD 170.5 billion by 2030. Saudi Arabia and the UAE together account for an estimated 82.6% of regional healthcare expenditure.
But the more important point is strategic. Saudi Arabia is increasingly positioning itself as a central node for health innovation access across the GCC, MENA, Africa, and parts of Asia. With over two billion Muslims globally, the Kingdom’s role as a convening market carries cultural and commercial weight that goes well beyond its own population of approximately 38 million.
Companies that succeed in Saudi—building local credibility, local structure, and a locally-proven track record—find that the regional conversation opens up considerably. It becomes easier to enter the UAE with a Saudi reference. Easier to engage Qatar or Kuwait. Easier to make the case in markets that look to the Kingdom as a regional benchmark.
But it’s not frictionless
None of this means the market is straightforward.
The same realities we see consistently still apply. The stakeholder landscape is complex. Decisions move through layers that take time to understand. Relationships have to be built before commercial conversations are appropriate. And localisation—whether of your product, your entity, or your team—is a genuine requirement, not an optional extra.
The opportunity is real. But it rewards companies that take the time to engage properly, not those trying to move quickly.
What this means in practice
The companies that tend to do well in Saudi healthcare right now share a few characteristics. They’re not the largest or most established players. They’re the ones who approach the market with genuine intent, willing to adapt, willing to invest in relationships, and willing to think in years rather than quarters.
They also tend to understand that Saudi is not simply a destination. It’s increasingly a platform, a place where innovation is shaped, credibility is built, and regional access is earned.
For companies that understand that distinction, the opportunity is significantly larger than it first appears.
At Welcome Health Ventures, this is the market we work in every day, helping companies move from initial interest to something credible, compliant, and positioned to grow.
Not just getting in. Getting it right.
